Dr. David Katz is the Founder and serves as CSO and President at Sparrow Pharmaceuticals. He served as Chief Executive Officer, President & Board Member at Sparrow Pharmaceuticals. He also serves as Advisor at VectorPoint Ventures. He is an Angel Investor. He had diverse pharmaceutical industry roles at Abbott from 1995-2012, and its successor AbbVie in 2013. Just prior to leaving to start Sparrow Pharmaceuticals, he led cross-functional teams for the clinical development of several experimental drugs. Previously, David initiated Abbott's pharmacogenetics program, built and led a clinical pharmacogenetics laboratory, provided personalized medicine strategic support for clinical trial teams across multiple therapeutic areas, and collaborated with commercial colleagues to map the potential of personalized medicine. He also led a joint research program with Myriad Genetics to discover new drug targets and lead compounds for major depression and research collaboration with Genset SA to find genetic risk factors for drug-induced liver injury. He earned his Ph.D. degree in Molecular Biochemistry & Biophysics from Yale University in 1992.